Phase III Trial Yields More Bad News for Genzyme

For the second time this week, Genzyme is announcing disappointing clinical-trial results. In a Phase 3 study, tolevamer liquid—a polymer-based treatment for Clostridium difficile associated diarrhea—failed to perform against the standard antibiotic treatment. Bloomberg has a nice summary of the trial and how it fits into Genzyme’s recent efforts to diversity its pipeline. Genzyme shares fell to 60.85 by the end of trading today, from a high of 64.87.

Rebecca is Xconomy's co-founder. Follow @

Trending on Xconomy